Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)2022-07-072022-07-072020-04-17Petersen, M., Zhang, F., Krinsky-McHale, S. J., Silverman, W., Lee, J. H., Pang, D., Hall, J., Schupf, N., & O'Bryant, S. E. (2020). Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands), 12(1), e12023. https://doi.org/10.1002/dad2.120232352-8729https://hdl.handle.net/20.500.12503/31541Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). Methods: Plasma samples were obtained from 398 members of a community-based cohort of adults with DS. A total of n = 186 participants were determined to be non-demented and without mild cognitive impairment (MCI) at baseline and throughout follow-up; n = 50 had prevalent MCI; n = 42 had prevalent AD. Results: The proteomic profile yielded an area under the curve (AUC) of 0.92, sensitivity (SN) = 0.80, and specificity (SP) = 0.98 detecting prevalent MCI. For detecting prevalent AD, the proteomic profile yielded an AUC of 0.89, SN = 0.81, and SP = 0.97. The overall profile closely resembled our previously published profile of AD in the general population. Discussion: These data provide evidence of the applicability of our blood-based algorithm for detecting MCI/AD among adults with DS.http://creativecommons.org/licenses/by-nc/4.0/Alzheimer's diseaseblood basedAlzheimer DiseaseDown SyndromeBiomarkersPlasmaArticleCopyright © 2020 The Authors.121